Abstract
Objective: The aim of this study was to assess the efficacy of memantine and compared sodium valproate in the prophylactic treatment of migraine.
Background: In migraine, prophylactic treatment aims to reduce the frequency, duration and intensity of migraine attacks and reduce disability. The rate of adherence to treatment is low due to adverse effects and lack of efficacy. Sodium Valproate is first-line treatment. In recent years, interest has increased in the use of glutamate receptor antagonists for migraine prophylaxis, such as Memantine.
Design/Methods: A single center, doble-blinded, controlled, randomized pilot clinical trial was conducted. The participants were randomized into the Memantine group who received doses of 10 mg twice a day or the group of Valproate sodium with 500 mg twice a day, for 12-week. Adverse events were monitored for safety assessment.
Results: A total of 33 patients were enrolled; 17 were assigned to receive memantine, and 16 to receive sodium valproate. The memantine group with an average of migraine attacks per month prior to treatment of 5.31 (SD ± 1.54) and after 12-week of treatment, an average of migraine attacks per month 0.93 (SD ± 1.49) with a decrease of 4.21 (SD ± 1.76) migraine attacks p << 0.001. In the sodium valproate group with an average of migraine attacks per month prior to treatment of 5.35 (SD ± 1.11) and after 12-week of treatment, an average of migraine attacks per month of 0.77 (SD ± 1.16), with a decrease of 4.5 (SD ± 1.39) migraine attacks p << 0.001. Adverse effects were mild severity, the most common was somnolence in both groups.
Conclusions: Memantine could be a new prophylactic treatment option in migraine, however, a clinical trial with a larger size is required to corroborate the findings of this study.
Disclosure: Ms. Vazquez Guevara has nothing to disclose. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
